BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism-Reference-Cited by-同舟云学术

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism

Published:2018-05-03 Issue:18 Volume:131 Page:2047-2059
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chen Jiaji G.¹,Liu Xia¹,Munshi Manit¹,Xu Lian¹,Tsakmaklis Nicholas¹,Demos Maria G.¹,Kofides Amanda¹,Guerrera Maria Luisa¹,Chan Gloria G.¹,Patterson Christopher J.¹,Meid Kirsten¹,Gustine Joshua¹,Dubeau Toni¹,Severns Patricia¹,Castillo Jorge J.¹²,Hunter Zachary R.¹²,Wang Jinhua³,Buhrlage Sara J.³,Gray Nathanael S.³,Treon Steven P.¹²,Yang Guang¹²

Affiliation:

1. Bing Center for Waldenstrom’s Macroglobulinemia,

2. Department of Medical Oncology, Dana Farber Cancer Institute, and

3. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA

Abstract

Key Points BTKCys481 mutation results in ERK1/2 mediated survival signaling and ibrutinib resistance in MYD88-mutated cells. BTKCys481 mutation confers a protective effect against ibrutinib on neighboring BTK wild-type cells through a paracrine mechanism.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/18/2047/1406067/blood811752.pdf

Reference36 articles.

1. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia;Yang;Blood,2013

2. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma;Wilson;Nat Med,2015

3. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib;Yang;Blood,2016

4. Ibrutinib in previously treated Waldenström’s macroglobulinemia;Treon;N Engl J Med,2015

5. Mutated MYD88 activates the BCR component SYK, and provides a rationale therapeutic target in Waldenstrom’s Macroglobulinemia [abstract];Munshi;Blood,2017

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Future Directions in the Frontline Management of Waldenström Macroglobulinemia;Hematology/Oncology Clinics of North America;2023-08

2. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib;Blood Advances;2023-06-16

3. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy;Clinical Cancer Research;2023-06-14

4. Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors;Pathology and Oncology Research;2023-04-19

5. BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia;Hemato;2023-04-13